Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07572006 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
A Phase 1 study, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 280
- Enrollment target
NCT07572006 is a Phase 1 study that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 280 participants.
The verdict
NCT07572006, a Phase 1 study, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 280 participants
- Enrollment target
Study Summary
The purpose of Part 1 (Dose Escalation) of the study is to assess how safe and tolerable JNJ-95804306 is and to find out the most suitable dose (recommended phase 2 dose \[RP2D\]) of JNJ-95804306. The purpose of Part 2 (Dose Expansion) is to further assess the safety of JNJ-95804306 and determine the anti-tumor activity alone and/or when administered in addition to standard of care (SoC) therapy at the putative RP2D(s) regimens in participants with hematological malignancies (cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system). For US sites: The purpose of Part 1 (Dose Escalation) of the study is to assess how safe and tolerable JNJ-95804306 is and to find out the most suitable dose (recommended phase 2 dose \[RP2D\]) of JNJ-95804306. The purpose of Part 2 (Dose Expansion) is to further assess the safety of JNJ-95804306 and determine the anti-tumor activity alone at the putative RP2D(s) regimens in participants with hematological malignancies (cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system).
Interventions
- DRUG JNJ-95804306
- DRUG AML SoC
- DRUG CLL/SLL SoC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2026-05-13 |
| Est. Completion | 2032-09-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07572006
The ClinicalTrials.gov registry entry for NCT07572006 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which JNJ-95804306 is the first listed.
NCT07572006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07572006 about?
NCT07572006 is a clinical study titled "A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies". The purpose of Part 1 (Dose Escalation) of the study is to assess how safe and tolerable JNJ-95804306 is and to find out the most suitable dose (recommended phase 2 dose \[RP2D\]) of JNJ-95804306. The purpose of Part 2 (Dose Expansion) is to further assess the safety of JNJ-95804306 and determine th...
What is the current status of trial NCT07572006?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 280 participants. The study started on 2026-05-13. Estimated completion is 2032-09-24.
What interventions are being tested in trial NCT07572006?
The interventions under investigation include: JNJ-95804306 (DRUG), AML SoC (DRUG), CLL/SLL SoC (DRUG).
Who is sponsoring clinical trial NCT07572006?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.